Physician profile
Morgan H Brinkman
NPI 1285225706
$6,320.42
in general payments reported to CMS, 2019-2025
22 companies · $2,010 in 2025
The $2,010 reported for 2025 was more than what 93% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $714 · 2023: $1,338 · 2024: $2,258 · 2025: $2,010.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,590 · Education: $15.93.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,590.25 |
| Education | $15.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,646.82 | 2022-2025 | |
| Genzyme Corporation | $598.28 | 2022-2025 | |
| Pfizer INC. | $597.61 | 2023-2025 | |
| Ardelyx, INC. | $515.10 | 2022-2025 | Ibsrela |
| Takeda Pharmaceuticals U.S.A., INC. | $465.28 | 2022-2025 | Entyvio, Eohilia, Gattex |
| Janssen Biotech, INC. | $305.49 | 2022-2025 | Tremfya, Stelara, Remicade |
| Lilly USA, LLC | $273.26 | 2024-2025 | Omvoh |
| Madrigal Pharmaceuticals | $252.13 | 2025 | Rezdiffra |
| Celgene Corporation | $247.00 | 2022-2024 | Zeposia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $246.43 | 2023-2025 | Trulance, Xifaxan |
| Phathom Pharmaceuticals, INC. | $227.41 | 2024-2025 | Voquezna |
| Aimmune Therapeutics, INC. | $225.24 | 2024-2025 | Zenpep |
| Regeneron Healthcare Solutions, INC. | $149.65 | 2022-2025 | Dupixent |
| Intercept Pharmaceuticals, INC. | $131.86 | 2023-2024 | Ocaliva |
| Ironwood Pharmaceuticals, INC | $120.89 | 2023-2024 | Linzess |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $113.19 | 2025 | Iqirvo |
| E.R. Squibb & Sons, L.L.C. | $92.84 | 2022 | |
| Nestle Healthcare Nutrition INC. | $30.64 | 2023 | |
| Mirum Pharmaceuticals, INC. | $24.79 | 2024 | Livmarli |
| Novo Nordisk INC | $24.47 | 2025 | |
| Ultragenyx Pharmaceutical INC. | $17.53 | 2022 | |
| Shield Therapeutics INC | $14.51 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Morgan Brinkman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.